AFF1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

CSF3R is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains CSF3R status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 2 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains ELL status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 2 clinical trials for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

PML is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains PML status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

RARA is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains RARA status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].